Clinical impact of drug-coated balloon treatment of coronary artery disease in elderly patients

被引:0
|
作者
Shin, Eun-Seok [1 ]
Jang, Mi Hee [1 ]
Kim, Sunwon [2 ]
Kang, Dong Oh [3 ]
Won, Ki-Bum [4 ]
Kim, Bitna [1 ]
Her, Ae-Young [5 ]
机构
[1] Univ Ulsan, Ulsan Univ Hosp, Dept Cardiol, Coll Med, Ulsan, South Korea
[2] Korea Univ, Korea Univ Ansan Hosp, Cardiovasc Ctr, Dept Internal Med,Coll Med, Ansan, South Korea
[3] Korea Univ, Korea Univ Guro Hosp, Cardiovasc Ctr, Dept Internal Med,Coll Med, Seoul, South Korea
[4] Chung Ang Univ, Gwangmyeong Hosp, Div Cardiol, Gwangmyeong, Gyeong, South Korea
[5] Kangwon Natl Univ, Coll Med, Dept Internal Med, Div Cardiol,Sch Med, Chunchon, South Korea
关键词
THERAPY; TRIALS;
D O I
10.26599/1671-5411.2025.01.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Data on drug-coated balloon (DCB) treatment in elderly patients are limited. This study was to evaluate the efficacy of DCB treatment in percutaneous coronary intervention (PCI) among elderly patients. Methods A retrospective analysis included 232 patients aged 75 years or older with coronary artery disease who underwent successful PCI using either DCB alone or in combination with drug-eluting stent (DES) based on pre-dilation results (DCB-based PCI). These patients were compared with 1818 elderly patients who underwent second-generation DES implantation (DES-only PCI). The endpoint was major adverse cardiovascular events (MACE) at 2-year follow-up. Results In the DCB-based PCI, 61.2% of patients received DCB-only treatment. Compared to DES-only PCI, the DCB-based PCI group had fewer stents (0.5 +/- 0.7 and 1.7 +/- 0.8, P < 0.001), shorter stent lengths (13.3 +/- 20.9 mm and 37.4 +/- 23.0 mm, P < 0.001), and lower usage of small stents with a diameter of 2.5 mm or less (15.6% and 28.7%, P = 0.010). The DCB-based PCI group exhibited lower rate of MACE (5.5% and 13.1%, P = 0.003), target vessel revascularization (1.1% and 5.6%, P = 0.017) and major bleeding (0.7% and 5.1%, P = 0.009) at 2-year follow-up. The reduced risk in 2-year MACE was consistently observed across various matching procedures, with the most significant reduction noted in target vessel revascularization and major bleeding. Conclusion The DCB-based PCI reduced stent burden, particularly in the usage of small diameter stents, and was associated with lower risks of MACE, target vessel revascularization, and major bleeding compared to DES-only PCI in elderly patients.
引用
收藏
页码:150 / 158
页数:9
相关论文
共 50 条
  • [41] Clinical research of drug-coated balloon after rotational atherectomy for severe coronary artery calcification
    Dong, Haozhe
    Shan, Yingguang
    Gong, Shenzhen
    Li, Ran
    Li, Yiming
    Lu, Xupeng
    Sun, Guoju
    BMC CARDIOVASCULAR DISORDERS, 2023, 23 (01)
  • [42] Clinical research of drug-coated balloon after rotational atherectomy for severe coronary artery calcification
    Haozhe Dong
    Yingguang Shan
    Shenzhen Gong
    Ran Li
    Yiming Li
    Xupeng Lu
    Guoju Sun
    BMC Cardiovascular Disorders, 23
  • [43] Drug-Coated Balloon-Only Percutaneous Coronary Intervention for the Treatment of De Novo Coronary Artery Disease: A Systematic Review
    Mohiaddin H.
    Wong T.D.F.K.
    Burke-Gaffney A.
    Bogle R.G.
    Cardiology and Therapy, 2018, 7 (2) : 127 - 149
  • [45] Impact of Dissection after Drug-Coated Balloon Treatment of De Novo Coronary Lesions: Angiographic and Clinical Outcomes
    Hui, Lin
    Shin, Eun-Seok
    Jun, Eun Jung
    Bhak, Youngjune
    Garg, Scot
    Kim, Tae-Hyun
    Sohn, Chang-Bae
    Choi, Byung Joo
    Kun, Liu
    Yuan, Song Lin
    Zhi, Wang
    Hao, Jiang
    Shi Zhentao
    Qiang, Tang
    YONSEI MEDICAL JOURNAL, 2020, 61 (12) : 1004 - 1012
  • [46] Moxy® drug-coated balloon: a novel device for the treatment of coronary and peripheral vascular disease
    Gutierrez-Chico, Juan Luis
    Regar, Evelyn
    van Geuns, Robert-Jan
    Garg, Scot
    Schultz, Carl
    van Mieghem, Nicolas
    Duckers, Henricus
    Serruys, Patrick W.
    EUROINTERVENTION, 2011, 7 (02) : 274 - 277
  • [47] Efficacy of Low-Pressure Inflation of Oversized Drug-Coated Balloon for Coronary Artery Disease
    Ueno, Katsumi
    Morita, Norihiko
    Kojima, Yoshinobu
    Kondo, Hiroki
    Takahashi, Hiroshi
    Minatoguchi, Shingo
    Higuchi, Sho
    Ando, Yu
    Esaki, Masayasu
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2020, 2020
  • [48] Paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease in elective clinical practice
    Merinopoulos, Ioannis
    Gunawardena, Tharusha
    Corballis, Natasha
    Bhalraam, U.
    Gilbert, Tim
    Maart, Clint
    Richardson, Paul
    Ryding, Alisdair
    Sarev, Toomas
    Sawh, Chris
    Sulfi, Sreekumar
    Wickramarachchi, Upul
    Wistow, Trevor
    Mohamed, Mohamed O.
    Mamas, Mamas A.
    Vassiliou, Vassilios S.
    Eccleshall, Simon C.
    CLINICAL RESEARCH IN CARDIOLOGY, 2023, 112 (09) : 1186 - 1193
  • [49] Paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease in elective clinical practice
    Ioannis Merinopoulos
    Tharusha Gunawardena
    Natasha Corballis
    U Bhalraam
    Tim Gilbert
    Clint Maart
    Paul Richardson
    Alisdair Ryding
    Toomas Sarev
    Chris Sawh
    Sreekumar Sulfi
    Upul Wickramarachchi
    Trevor Wistow
    Mohamed O. Mohamed
    Mamas A. Mamas
    Vassilios S. Vassiliou
    Simon C. Eccleshall
    Clinical Research in Cardiology, 2023, 112 : 1186 - 1193
  • [50] Clinical Outcomes of Drug-Coated Balloon Angioplasty in Peripheral Artery Disease Patients With End-Stage Renal Disease
    Wang, Sheng-Xing
    Xiong, Qi-Qiu
    Ren, Hua-Liang
    Zheng, Kai
    Sun, Ming-Sheng
    Zhang, Wangde
    Li, Chun-Min
    JOURNAL OF ENDOVASCULAR THERAPY, 2023,